Infectious Diseases
Tested and proven testing solutions
COVID-19
MiRXES offers complete COVID-19 testing solutions, starting from sample collection and preservation, through easy and reliable RNA extraction, to tested and proven SARS-CoV-2 RT-PCR diagnostic tests and mutation panels for quick identification of key variants.
Ordering Information
Sample Collection & Processing Solutions
Swab Collection System
Collect, handle, and store nasal and throat swab samples safely and stably (up to two weeks at room temperature).
Saliva Collection Kit
Easy and convenient collection of saliva samples which can be transported and stored stably up to 15 days at room temperature.
RNA Extraction Kits
MAGec RNA Extraction Kits for easy and reliable RNA extraction using guanidine-based lysis and magnetic bead-based isolation.
RNA Extraction Instruments
Automated extraction system optimized for MAGec RNA Extraction Kits. Suitable for medium- and high-throughput workflows.
RT-PCR Testing
Solutions
Fortitude 2.1 Test Kit
Tested and proven RT-PCR test detecting 2 SARS-CoV-2 ORF regions. More than 7 million tests deployed in over 45 countries.
Fortitude 3.0 Test Kit
Updated Fortitude COVID-19 RT-PCR test detecting 2 SARS-CoV-2 genes (ORF and N). Able to detect all variants of concern.
Fortitude Syndromic Panel
Fortitude SARS-CoV-2 & Flu A/B test kit. Detects 2 SARS-CoV-2 genes (ORF and N).
CoVClear Mutation Panel
RUO test to detect key SARS-CoV-2 mutations for early identification of COVID-19 positive patients infected by variants of concern.
November 2021 Update: SARS-CoV-2 Variants
The World Health Organization (WHO) has defined a SARS-CoV-2 isolate as a variant of interest (VOI) if it is phenotypically changed compared to a reference isolate of has a genome with mutations that lead to amino acid changes associated with established or suspected phenotypic implications; AND has been identified to cause community transmission/multiple COVID-19 cases/clusters, or has been detected in multiple countries.
A VOI is further classified as a variant of concern (VOC) if, through a comparative assessment, it has been demonstrated to be associated with:
- Increase in transmissibility of detrimental change in COVID-19 epidemiology;
- Increase in virulence or change in clinical disease presentation; or
- Decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics.
WHO-designated SARS-CoV-2 variants of concern (VOCs), as of 29 November 2021.
WHO Label | Pango Lineage | First identified | Spike protein substitutions |
|---|---|---|---|
Alpha | B.1.1.7 | United Kingdom | N501Y, 69del, 70del, 144del, (E484K*), (S494P*), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*) |
Beta | B.1.351 | South Africa | D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, A701V |
Gamma | P.1 | Brazil | L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I |
Delta | B.1.617.2 | India | T19R, (V70F*), T95I, G142D, E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), L452R, T478K, D614G, P681R, D950N |
Omicron | B.1.1.529 | South Africa | – |
WHO-designated SARS-CoV-2 variants of interest (VOIs), as of 29 November 2021.
WHO Label | Pango Lineage | First identified | Spike protein substitutions |
|---|---|---|---|
Epsilon | B.1.427 | US (California) | L452R, D614G |
Epsilon | B.1.429 | US (California) | S13I, W152C, L452R, D614G |
Eta | B.1.525 | UK/Nigeria | A67V, 69del, 70del, 144del, E484K, D614G, Q677H, F888L |
Iota | B.1.526 | US (New York) | L5F, (D80G*), T95I, (Y144-*), (F157S*), D253G, (L452R*), (S477N*), E484K, D614G, A701V, (T859N*), (D950H*), (Q957R*) |
Kappa | B.1.617.1 | India | (T95I), G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H |
None | B.1.617.3 | India | T19R, G142D, L452R, E484Q, D614G, P681R, D950N |
Lambda | C.37 | Peru | G75V, T76I, 246-252del, L452Q, F490S, D614G, T859N |
Mu | B.1.621 | Colombia | E484K, N501Y, P681H |
Detection of key SARS-CoV-2 variants by MiRXES RT-PCR test kits
The MiRXES R&D team is constantly tracking the World Health Organization’s designation of new VOCs and VOIs and has performed in silico analyses to determine the sequence homology between the MiRXES SARS-CoV2 RT-PCR primers and all SARS-CoV-2 sequences, including those of specific variants.
Overall, >99.4% of aligned sequences have 100% homology to either the ORF or N gene target sequence of MiRXES RT-PCR test kits.
Percentage of aligned sequences in the GISAID database that have 100% homology to the primer (probe) sequence of the MiRXES RT-PCR test kits, as of 29 November 2021:
Sequence homology with | Fortitude 2.1 | Fortitude Syndromic Panel |
|---|---|---|
All SARS-CoV-2 ORF target sequences | 99.4 | 97.6 |
All SARS-CoV-2 N gene target sequences | – | 98.1 |
Delta (B.1.617.2) | 100.00 | 99.90 |
Alpha (B.1.1.7) | 99.79 | 99.99 |
Beta (B.1.351) | 100.00 | 99.96 |
Gamma (P.1) | 99.98 | 99.98 |
Omicron (B.1.1.529) | 100.00 | 100.00 |
Lambda (C.37) | 100.00 | 99.66 |
Mu (B.1.621) | 100.00 | 100.00 |
SOCIAL MEDIA
- Genomics
- Clinical Sequencing
- Research Sequencing
- Cancer Screening
- GASTROClear for Patients
- GASTROClear for Medical Professionals
- Cancer Treatment Selection
- APEX Tissue Panel for Medical Professionals
- Infectious Diseases
- Fortitude 2.1
- Fortitude 3.0
- Fortitude Syndromic Panel
- CoVClear Mutation Panel
- Swab & Saliva Collection
- RNA Extraction Kit & Instruments